

9th February, 2023

BSE Limited

P.J. Towers, Dalal Street, Fort, Mumbai- 400 001

BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

(Collectively, the "Stock Exchanges")

Disclosure under Regulation 30 read with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') - Re-classification of certain entities from 'Promoter Group' category to 'Public' category of Piramal Pharma Limited ('the Company')

Dear Sir / Madam,

Kindly refer to our letter dated 2nd February, 2023 on the subject.

The Board of Directors of the Company, at its meeting held on 8th February, 2023, considered and approved the requests received from the following entities for re-classification from 'Promoter Group' category to 'Public' category of the Company based on confirmations received from said entities in line with Regulation 31A of the SEBI Listing Regulations, subject to approval of the Stock Exchanges and/or other approval, if any, as may be required:

Sr.	Name of the Entity	No. of Equity Shares	% of
No.		held	shareholding
1.	Piramal Foundation	0	-
2.	Piramal Udgam Data Management Solutions	0	-
3.	Piramal Foundation For Education Leadership	0	-
4.	Kaivalya Education Foundation	0	-
5.	India Resurgence ARC Private Limited	0	-
6.	India Resurgence Asset Management Business Private	0	-
	Limited		
7.	The Address Makers Developers Private Limited	0	-
8.	Kosamba Glass Deco Private Limited	0	-
9.	Ansa Deco Glass Private Limited	0	-
10.	PRL Agastya Private Limited	0	-

In accordance with Regulation 31A of the SEBI Listing Regulations, please find enclosed the certified true copy of the resolution passed by the Board of Directors of the Company in this regard.

You are requested to kindly take the above, on record.

Thanking you,

Yours truly,

For Piramal Pharma Limited

Tanya Sanish **Company Secretary**

Encl: a/a



CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF PIRAMAL PHARMA LIMITED HELD ON WEDNESDAY, 8^{TH} FEBRUARY, 2023

Approval for re-classification from 'Promoter Group' category to 'Public' category as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

"RESOLVED THAT pursuant to the provisions of Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ('SEBI Listing Regulations') and subject to the approval of the stock exchanges where the securities of the Company are listed i.e. BSE Listed ('BSE') and National Stock Exchange of India Limited ('NSE') (together referred to as 'Stock Exchanges'), and/or such other approval(s), if any, as may be required in this regard, the approval of the Board of Directors be and is hereby accorded towards the re-classification of the following entities ('Re-classified Entities') from 'Promoter Group' category to 'Public Shareholder' category, as each of these entities comply with the conditions laid down under Regulation 31A(3)(b) of the SEBI Listing Regulations:

Sr. No.	Names of Re-classified Entities	No. of Equity Shares and % of shareholding
1.	Piramal Foundation	0
2.	Piramal Udgam Data Management Solutions	0
3.	Piramal Foundation For Education Leadership	0
4.	Kaivalya Education Foundation	0
5.	India Resurgence ARC Private Limited	0
6.	India Resurgence Asset Management Business Private Limited	0
7.	The Address Makers Developers Private Limited	0
8.	Kosamba Glass Deco Private Limited	0
9.	Ansa Deco Glass Private Limited	0
10.	PRL Agastya Private Limited	0

RESOLVED FURTHER THAT upon receipt of the approval from the Stock Exchanges for reclassification of the above mentioned entities from 'Promoter Group' to 'Public' Shareholder, the Company shall effect such re-classification in the Statement of Shareholding Pattern from the immediate succeeding quarter under Regulation 31 of SEBI Listing Regulations and other applicable provisions of laws, if any;

RESOLVED FURTHER THAT the Executive Directors and Ms. Tanya Sanish, Company Secretary of the Company be and are hereby severally authorised and empowered to do, execute and perform all or any of the following acts, deeds, matters and things viz:

- a. To make, execute and file such application, information and other documents with and represent the Company before the Stock Exchanges and / or other regulatory authorities and seek necessary approvals and consents, if any, for re-classification of the Re-classified Entities;
- b. Communicate and liaise with any regulatory authorities (including Stock Exchanges and SEBI) or third parties as may be required under applicable laws; and
- c. To do all acts, matters, deeds and things necessary or desirable in connection with or incidental or consequential to the above, with further power to delegate the powers conferred on them by this resolution to any Officer(s) of the Company or to any other person(s) as they may deem fit and proper;



RESOLVED FURTHER THAT the certified true copy of the aforesaid resolution under the signature of any of the Directors or Key Managerial Personnel of the Company be forwarded to such persons or authorities as may be required from time to time."

For Piramal Pharma Limited

Tanya Sanish Company Secretary